| Autor: |
Andrés Cervantes, Josep Tabernero, José Baselga, Premal Patel, Yibing Yan, Kui Lin, Raymond D. Meng, Sandra M. Sanabria Bohórquez, Wai Y. Chan, Michelle Nannini, Jin Zhu, Nageshwar Budha, Luna Musib, Juan Manuel Sanchis-García, Rafael Morales-Barrera, José Alejandro Pérez-Fidalgo, Teresa Macarulla, Mafalda Oliveira, Susana Roselló, Desamparados Roda, Cristina Saura |
| Rok vydání: |
2023 |
| DOI: |
10.1158/2159-8290.22531864 |
| Popis: |
Supplementary Table S1. IC50 values of ipatasertib on cell viability in cell lines with or without alterations in PTEN or PIK3CA. Supplementary Table S2. Percent tumor growth inhibition (%TGI) in xenograft models with or without alterations in PTEN or PIK3CA. Supplementary Table S3. PI3K/Akt pathway status in archival tumors. Supplementary Table S4. Reasons for discontinuation of study. Supplementary Table S5. Common adverse events for ipatasertib in {greater than or equal to} 10% of patients in any presented group. Supplementary Table S6. All Grade {greater than or equal to} 3 adverse events related to ipatasertib. Supplementary Table S7. Hemoglobin A1C (HgbA1C) values for patients who had both pre-treatment and post-treatment values in Stages 1 and 2. Supplementary Table S8. Summary data for patients with best radiographic stable disease (SD) by RECIST version 1.0 criteria. Supplementary Figure S1. Exposure plots confirm that exposures achieved in patients in the dose-escalation stage (right side) correlated with exposures in preclinical models at TGI90 (left side). Supplementary Figure S2. Relationship between exposure of ipatasertib to the most common ipatasertib-related AEs of fatigue, diarrhea, nausea, and rash. Supplementary Figure S3. Suppression of pGSK3β in platelet-rich plasma versus ipatasertib concentrations. Supplementary Figure S4. Pharmacodynamic (PD) dose-dependent elevations in glucose and insulin following treatment with ipatasertib. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
